会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Indole derivatives useful A.O. for the treatment of osteoporosis
    • 吲哚衍生物有用A.O. 用于治疗骨质疏松症
    • US06506758B2
    • 2003-01-14
    • US09975347
    • 2001-10-11
    • Stefania GagliardiGuy Marguerite Marie Gerard NadlerPietro A T Novella
    • Stefania GagliardiGuy Marguerite Marie Gerard NadlerPietro A T Novella
    • C07D40112
    • C07D401/12C07D209/18
    • A compound of formula (I): or a salt thereof, or a solvate thereof, wherein: A represents an optionally substituted aryl group or an optionally substituted heterocyclyl group; Ra represents —CO—NRsRt wherein Rs and Rt each independently represent hydrogen, alkyl, substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocyclyl or an optionally substituted heterocyclylalkyl group, or Rs and Rt together with the nitrogen to which they are attached form a heterocyclyl group; R1 and R2 each independently represents hydrogen, hydroxy, amino, alkoxy, optionally substituted aryloxy, optionally substituted benzyloxy, alkylamino, dialkylamino, halo, trifluoromethyl, trifluoromethoxy, nitro, alkyl, carboxy, carbalkoxy, carbamoyl, alkylcarbamoyl, or R1 and R2 together represent methylenedioxy, carbonyldioxy or carbonyldiamino; and R3 represents hydrogen, alkanoyl, alkyl, aminoalkyl, hydroxyalkyl, carboxyalkyl, carbalkoxyalkyl, carbamoyl or alkylsulphonyl and arylsulphonyl; a process for the preparation of such a compound, a pharmaceutical composition containing such a compound and the use of such a compound or composition in medicine.
    • 式(I)化合物或其盐或其溶剂化物,其中:A表示任选取代的芳基或任选取代的杂环基; Ra表示-CO-NRsRt,其中R 5和R 5各自独立地表示氢,烷基 取代的烷基,任选取代的烯基,任选取代的芳基,任选取代的芳基烷基,任选取代的杂环基或任选取代的杂环基烷基,或R 5和R 5与它们所连接的氮一起形成杂环基; R 1和R 2各自独立地表示 氢,羟基,氨基,烷氧基,任选取代的芳氧基,任选取代的苄氧基,烷基氨基,二烷基氨基,卤素,三氟甲基,三氟甲氧基,硝基,烷基,羧基,烷氧基,氨基甲酰基,烷基氨基甲酰基,或R1和R2一起代表亚甲二氧基,羰基二氧基或羰基二氨基; 烷基,氨基烷基,羟基烷基,羧基烷基,烷氧基烷基,氨基甲酰基或烷基磺酰基和芳基磺酰基; 制备这种化合物的方法,含有这种化合物的药物组合物和这种化合物或组合物在医药中的用途。
    • 5. 发明授权
    • Azalicyclooctane derivatives as anti-arrhythmic agents
    • 作为抗心律失常剂的氮杂环辛烷衍生物
    • US5712284A
    • 1998-01-27
    • US578667
    • 1996-02-14
    • Guy Marguerite Marie Gerard NadlerMichel Louis Souchet
    • Guy Marguerite Marie Gerard NadlerMichel Louis Souchet
    • C07D453/02A61K31/435A61K31/44A61P9/06A61P9/08A61P9/10C07D451/04C07D453/06
    • C07D451/04
    • A compound of formula (I) or a salt thereof, or a solvate thereof: ##STR1## wherein B represents a C.sub.1-4 n-alkylene group wherein each carbon is optionally substituted by a C.sub.1-6 alkyl group; Z represents a bond, CH.sub.2, (CH.sub.2).sub.2 or X--CH.sub.2 --CH.sub.2 wherein X represents O or S; D represents CO, SO.sub.2, NH--CO or NH--SO.sub.2 ; T represents a bond and U represents CH.sub.2 or T represents CH.sub.2 and U represents a bond; Q represents aryl, aralkyl, aralkenyl or aralkynyl, wherein the aryl moiety may be unsubstituted or substituted with 1 to 5 substituents selected from the list consisting of nitre, halogen, alkylsulfonamido, acylamido, 1H-imidazolyl, alkyl or haloalkyl, or Q represents substituted or unsubstituted: furanyl, pyranyl, thienyl, thiazolyI, imidazolyl, triazolyl or the benzo fused equivalents or furanyl, pyranyl, thienyl, thiazolyl, 1H-imidazolyl, or triazolyl, indolyl, oxoindolyl, indenyl, isoindenyl, indazolyl, indolizinyl or pyridinyl or cycloalkyl optionally fused to an aryl group; R.sub.1, R.sub.2, and R.sub.3 each independently represents H, alkyl, OH or alkoxy or, if attached to adjacent carbon atoms, any two of R.sub.1, R.sub.2, and R.sub.3 together with the carbon atoms to which they are attached may form a fused heterocyclic ring of five or six atoms wherein one, two or three of the said atoms are oxygen or nitrogen; Ar represents substituted or unsubstituted aryl, wherein the optional substituents are the above defined R.sub.1, R.sub.2, and R.sub.3 or Ar represents a substituted or unsubstituted heteroaryl group; a process for the preparation of such a compound and the use of such a compound in medicine.
    • PCT No.PCT / EP94 / 02299 Sec。 371日期:1996年2月14日 102(e)1996年2月14日PCT PCT 1994年7月11日PCT公布。 公开号WO95 / 03301 日期:1995年2月2日一种式(I)化合物或其盐或其溶剂合物:其中B表示C 1-4正亚烷基,其中每个碳任选被C 1-6取代 烷基; Z表示键,CH 2,(CH 2)2或X-CH 2 -CH 2,其中X表示O或S; D表示CO,SO2,NH-CO或NH-SO2; T表示键,U表示CH 2或T表示CH 2,U表示键; Q表示芳基,芳烷基,芳烯基或芳炔基,其中芳基部分可以是未取代的或被1至5个选自硝基,卤素,烷基磺酰氨基,酰基酰氨基,1H-咪唑基,烷基或卤代烷基的取代基取代,或Q表示取代的 或未取代的:呋喃基,吡喃基,噻吩基,噻唑基,咪唑基,三唑基或苯并稠合的等价物或呋喃基,吡喃基,噻吩基,噻唑基,1H-咪唑基或三唑基,吲哚基,氧代吲哚基,茚基,异茚基,吲唑基,吲嗪基或吡啶基或​​环烷基 任选地与芳基稠合; R 1,R 2和R 3各自独立地表示H,烷基,OH或烷氧基,或者如果连接到相邻碳原子上,则R 1,R 2和R 3中的任何两个与它们所连接的碳原子一起可以形成稠合杂环 其中一个,两个或三个所述原子是氧或氮; Ar表示取代或未取代的芳基,其中任选取代基为上述定义的R 1,R 2和R 3或Ar表示取代或未取代的杂芳基; 制备这种化合物的方法和这种化合物在医药中的用途。
    • 6. 发明授权
    • Quinoline derivatives as NK-2 and NK-3 receptor ligands
    • 喹啉衍生物作为NK-2和NK-3受体配体
    • US06613770B1
    • 2003-09-02
    • US09856385
    • 2001-09-28
    • Carlo FarinaGiuseppe GiardinaMario GrugniGuy Marguerite Marie Gerard NadlerLuca Francesco Raveglia
    • Carlo FarinaGiuseppe GiardinaMario GrugniGuy Marguerite Marie Gerard NadlerLuca Francesco Raveglia
    • A61K314725
    • C07D401/06C07D215/52C07D401/14
    • A compound, or a solvate or a salt thereof, of formula (I): wherein R is linear or branched alkyl; R1 represents hydrogen or up to four optional substituents selected from the list consisting of: C1-6 alkyl, C1-6 alkenyl, aryl, C1-6 alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, C1-6 alkoxycarbonyl, trifluoromethyl, acyloxy, phthalimido, amino or mono- and di-C1-6 alkylamino; R2 represents a moiety —(CH2)n—NY1Y2 wherein n is an integer in the range of from 1 to 9, Y1 and Y2 are independently selected from hydrogen; C1-6-alkyl; C1-6 alkyl substituted with hydroxy, C1-6 alkylamino or bis (C1-6 alkyl) amino; C1-6-alkenyl; aryl or aryl-C1-6-alkyl or Y1 and Y2 together with the nitrogen atom to which they are attached represent an optionally substituted N-linked single or fused ring heterocyclic group; R3 is branched or linear C1-6 alkyl, C3-7 cycloalkyl, C4-7 cycloalkylalkyl, optionally substituted aryl, or an optionally substituted single or fused ring aromatic heterocyclic group; and R4 represents hydrogen or alkyl or R4 and R together with the carbon atom to which they are attached form an optionally substituted C3-12 cycloalkyl group; a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and composition in medicine.
    • 式(I)的化合物或其溶剂化物或其盐:其中R是直链或支链烷基; R1代表氢或最多四个选自下列的任选取代基:C 1-6烷基,C 1-6烯基 芳基,C 1-6烷氧基,羟基,卤素,硝基,氰基,羧基,甲酰胺基,磺酰氨基,C 1-6烷氧基羰基,三氟甲基,酰氧基,苯二甲酰亚氨基,氨基或单-C2和二-C6烷基氨基; R2代表 - (CH2)n-NY1Y2其中n是1至9的整数,Y1和Y2独立地选自氢; C 1-6 - 烷基; 被羟基,C 1-6烷基氨基或双(C 1-6烷基)氨基取代的C 1-6烷基; C 1-6 - 烯基; 芳基或芳基-C 1-6 - 烷基或Y1和Y2与它们所连接的氮原子一起表示任选取代的N-连接的单或稠环杂环基; R 3是支链或直链C 1-6烷基,C 3-7 环烷基,C 4-7环烷基烷基,任选取代的芳基或任选取代的单环或稠环芳族杂环基; R 4表示氢或烷基或R 4,R与它们所连接的碳原子一起形成任选取代的C 3-12环烷基; 制备这种化合物的方法,包含这些化合物的药物组合物以及这些化合物和组合物在医药中的用途。
    • 9. 发明授权
    • Indole derivatives for the treatment of osteoporosis
    • 吲哚衍生物用于治疗骨质疏松症
    • US06903117B2
    • 2005-06-07
    • US10300332
    • 2002-11-20
    • Carlo FarinaStefania GagliardiGuy Marguerite Marie Gerard Nadler
    • Carlo FarinaStefania GagliardiGuy Marguerite Marie Gerard Nadler
    • B82B1/00C07D209/18C07D401/12C07D401/14C07D403/12C07D413/12C07D451/02C07D451/04C07D455/02C07D471/04C07D471/08C07D471/16A61K31/454
    • C07D451/02C07D209/18C07D401/12C07D401/14C07D403/12C07D413/12C07D451/04C07D455/02C07D471/04C07D471/08
    • A compound of formula (I): or a salt thereof, or a solvate thereof, wherein Ra represents a group R5 which is hydrogen, alkyl or optionally substituted aryl and Rb represents a moiety of formula (a): wherein X represents a hydroxy or an alkoxy group wherein the alkyl group may be substitued or unsubstituted or X represents a group NRsRt wherein Rs and Rt each independently represent hydrogen, alkyl, substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, optionally substituted arylalkyl, an optionally substituted heterocyclic group or an optionally substituted heterocyclylalkyl group, or Rs and Rt together with the nitrogen to which they are attached form a heterocyclic group; R1 represents an alkyl or a substituted or unsubstituted aryl group; and R2, R3 and R4 each independently represent hydrogen, alkyl, aryl or substituted aryl; R6 and R7 each independently represent hydrogen, hydroxy, amino, alkoxy, optionally substituted aryloxy, optionally substituted benzyloxy, alkylamino, dialkylamino, halo, trifluoromethyl, trifluoromethoxy, nitro, alkyl, carboxy, carbalkoxy, carbamoyl, alkylcarbamoyl, or R6 and R7 together represent methylenedioxy, carbonyldioxy or carbonyldiamino; and R8 represents hydrogen, hydroxy, alkynoyl, alkyl, aminoalkyl, hydroxyalkyl, carboxyalky, carbalkoxyalkyl, carbamoyl or aminosulphonyl; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.
    • 式(I)化合物或其盐或其溶剂合物,其中R a表示R 5基团,其为氢,烷基或任选取代的芳基,R b表示式(a ):其中X表示羟基或烷氧基,其中烷基可以被取代或未被取代,或X表示基团NR 1 R t R 3和R 3各自独立地表示氢,烷基,取代的烷基,任选取代的烯基,任选取代的芳基,任选取代的芳烷基,任选取代的杂环基或任选取代的杂环基烷基, 和它们所连接的氮一起形成杂环基; R 1表示烷基或取代或未取代的芳基; 和R 2,R 3和R 4各自独立地表示氢,烷基,芳基或取代的芳基; R 6和R 7各自独立地表示氢,羟基,氨基,烷氧基,任选取代的芳氧基,任选取代的苄氧基,烷基氨基,二烷基氨基,卤素,三氟甲基,三氟甲氧基,硝基, 烷基,羧基,烷氧基,氨基甲酰基,烷基氨基甲酰基或R 6和R 7一起代表亚甲二氧基,羰基二氧基或羰基二氨基; R 8表示氢,羟基,炔酰基,烷基,氨基烷基,羟基烷基,羧基,烷氧基烷基,氨基甲酰基或氨基磺酰基; 制备这种化合物的方法,含有这种化合物的药物组合物和这种化合物在医药中的用途。
    • 10. 发明授权
    • Nitro-benzamides useful as anti-arrhythmic agents
    • 可用作抗心律不齐剂的硝基苯甲酰胺
    • US06570037B2
    • 2003-05-27
    • US10060760
    • 2002-01-30
    • Guy Marguerite Marie Gerard NadlerMichel Jean Roger Martin
    • Guy Marguerite Marie Gerard NadlerMichel Jean Roger Martin
    • C07C23365
    • C07C233/78
    • A compound of formula (I): or a salt thereof, or a solvate thereof, wherein Ar represents substituted or unsubstituted aryl, wherein the optional substituents are selected from alkyl, hydroxy or alkoxy or, if attached to adjacent carbon atoms any two substituents together with the carbon atoms to which they are attached may form a fused heterocyclic ring of five to six atoms wherein one, two or three of the said atoms are oxygen or nitrogen; A represents a C1-4 n-alkylene group wherein each carbon is optionally substituted by 1 or 2 C1-6 alkyl groups; R1 represents hydrogen, alkyl, alkenyl or cycloalkyl; one or two of of the group of R2, R3 and R4 represents nitro the remaining members of the group of R2, R3 and R4 represent hydrogen; X represents a —CO—NH— moiety; and Z represents C2-4 n-alkylene group wherein each carbon is optionally substituted 1 or 2 C1-6 alkyl groups; a process for preparing such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.
    • 式(I)化合物或其盐或其溶剂合物,其中Ar表示取代或未取代的芳基,其中任选的取代基选自烷基,羟基或烷氧基,或者如果连接到相邻的碳原子上,则任意两个取代基在一起 与它们连接的碳原子可以形成五至六个原子的稠合杂环,其中一个,两个或三个所述原子是氧或氮; A表示C 1-4的正亚烷基,其中每个碳任选被1或2个C 1-6烷基取代; R1代表氢,烷基,烯基或环烷基; R 2,R 3和R 4中的一个或两个表示硝基,R 2,R 3和R 4中的剩余成员表示氢; X表示-CO-NH-部分; Z表示C2-4正亚烷基,其中每个碳任选地被1或2个C 1-6烷基取代; 制备这种化合物的方法,包含这些化合物的药物组合物和这些化合物在医药中的用途。